Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kazia Therapeutics (KZIA) Long-Term Investments (2009 - 2019)

Kazia Therapeutics (KZIA) posted Long-Term Investments of $117679.3 for Q2 2019, down 94.04% on a QoQ basis from $2.0 million in Q4 2018, and down 96.41% year-over-year from $3.3 million in Q2 2018.

Kazia Therapeutics (KZIA) has 5 years of Long-Term Investments data on file, last reported at $117679.3 in Q2 2019.

  • In Q2 2019, Long-Term Investments fell 96.41% year-over-year to $117679.3; the TTM figure through Jun 2019 stood at $117679.3 (down 96.41% YoY), while the FY2019 annual figure was $117679.3, down 96.41% from the prior year.
  • Long-Term Investments slipped to $117679.3 in Q2 2019, from $2.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $5.8 million in Q4 2016 and bottomed at $16280.4 in Q2 2016.
  • A 4-year average of $1.9 million and a median of $1.0 million in 2018 frame the typical range for Long-Term Investments.
  • Annual changes were most pronounced in 2018 — Long-Term Investments surged 19757.38% — and 2019, when it plunged 96.41%.
  • Year by year, Long-Term Investments stood at $5.8 million in 2016, then tumbled by 99.72% to $16526.6 in 2017, then soared by 11839.25% to $2.0 million in 2018, then slumped by 94.04% to $117679.3 in 2019.
  • The last three Long-Term Investments figures came in at $117679.3 (Q2 2019), $2.0 million (Q4 2018), and $3.3 million (Q2 2018), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 505,194.89
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.75 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 9.79 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 22.17 Mn
10 Kazia Therapeutics 1.55 Bn 1.55 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2019 117,679.34
Dec 31, 2018 1.97 Mn
Jun 30, 2018 3.28 Mn
Jun 30, 2017 16,526.63
Dec 31, 2016 5.85 Mn
Jun 30, 2016 16,280.35
Jun 30, 2009 -5.08 Mn